ResearcherTaipei Medical UniversityNo recent work listed
Tsu-Yi Chao
Matched on OpenAlex author ID A5111818811. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2018: 1 paper · 2019: none · 2020: 1 paper
Papers 2
- Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cells9040911↗
- The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Last author DOI 10.1007/s10585-018-9919-5↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chi‐Tai Yeh · 2 shared papers, 2018–2020 · strength 0.22
- Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
- Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗
- Shiue‐Wei Lai · 2 shared papers, 2018–2020 · strength 0.22
- Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
- Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗
- Alexander T.H. Wu · 1 shared paper, 2020 · strength 0.13
- Wen‐Chiuan Tsai · 1 shared paper, 2018 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.